| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |